Description: Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Home Page: www.seegene.com
Taewon Building
Seoul,
05548
South Korea
Phone:
82 2 2240 4000
Officers
Name | Title |
---|---|
Jong-Ki Kim | Managing Director |
Hak-Soo Lee | VP |
Dr. Jong-Yoon Chun | Founder, CEO, CTO & Director |
Jong-Gi Cheon | VP and Chairman of Seegene Medical Foundation |
Hae-Joon Park | Managing Director |
Mr. Jin-Soo Choi | Exec. VP & Director |
Mr. Byung-Kyun Ham | Sr. Managing Director |
Mr. Boo-Hyun Yang | Sr. Managing Director |
Dr. Richard S. Creager Ph.D. | CEO of Seegene Technologies |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0 |
Price-to-Sales TTM: | 0.6505 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 1008 |